Tiziana Life Sciences Completes Enrollment for Key Phase 2a MS Trial; Topline Data Expected Late Q3 2026
TLSA sits 47% above its 52-week low of $1.14.
Summary
Tiziana Life Sciences has completed patient enrollment for its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis, with topline data anticipated in late Q3 2026. This marks a significant step forward for its lead candidate.
Key Events · Product Development and Regulatory · TLSA
-
Phase 2a MS Trial Enrollment Completed
Tiziana Life Sciences has fully enrolled its randomized, double-blind, placebo-controlled Phase 2a clinical trial (INFORM-MS) for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
-
Topline Data Expected Late Q3 2026
Topline results from the 48-patient study are anticipated in late Q3 2026 and will also be presented at the 10th joint ACTRIMS and ECTRIMS meeting in October 2026.
-
First Placebo-Controlled Study
This trial is the first placebo-controlled study of intranasal foralumab, a critical step for robust data generation for the novel anti-CD3 monoclonal antibody.
-
Addresses 'Going Concern' Context
This clinical progress is particularly important following the company's recent 'going concern' warning, demonstrating advancement of its lead asset.
Analysis · TLSA · Life Sciences
This announcement confirms the successful completion of patient enrollment for Tiziana's pivotal Phase 2a clinical trial of intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis. This milestone de-risks trial execution and sets a clear timeline for topline data in late Q3 2026, which is critical for the company, especially given its recent 'going concern' disclosure. The trial is the first placebo-controlled study for this novel therapy, making its results highly anticipated for the company's future.
At the time of this filing, TLSA was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.1M. The 52-week trading range was $1.14 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.